Medtronic teams with Masimo, 60+ others to eliminate preventable patient deaths by 2020: 6 takeaways
Fridley, Minn.-based Medtronic and Irvine, Calif.-based Masimo Corp. are partnering to share anonymous patient data with each other and researchers to help predict health problems, the Minnesota Star Tribune reports.
Here's what you need to know.
1. Medtronic is joining the Patient Safety Movement Foundation. Masimo CEO Joe Kiani founded the foundation.
2. Medtronic will provide $5 million to the foundation and will share data from its devices the foundation will incorporate into its predictive analytical program.
3. The program is developing code which would use patient data to predict health problems for other patients in real time.
Mr. Kiani told the StarTribune, “We wanted to show the healthcare industry, hospitals, everyone, that when it comes to patient safety we all have to collaborate together. Even fierce competitors.”
4. The foundation has the support of more than 60 healthcare technology companies including GE Healthcare, IBM Watson Health, Philips Healthcare and Zoll Medical.
5. Medtronic will share patient-level information from its monitoring and diagnostic devices. Proprietary data or information from its implantable pacemakers will not be shared.
6. The foundation's main goal is to end preventable patient deaths in healthcare settings by 2020.
More articles on infection control:
Wilton Surgery Center's Amanda Gunthel receives patient safety award
HHS' new report on carcinogens adds 7 substances: 5 things to know
FDA is finding difficulty in hiring & maintaining employees; how will this impact the drug approval process — 5 notes
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Participants race to increase colon cancer awareness during 2017 Greater Chattanooga Rump Run 5K and Fun Walk: 4 takeaways
- US woman dies from superbug resistant to 26 antibiotics — 8 things to know
- Healthcare nanotechnology market to grow at a CAGR above 12% till 2024
- American Anesthesiology to exhibit at ASA's Practice Management 2017: 3 things to know
- Gastroenteropancreatic neuroendocrine tumor patients utilize combination therapy: 5 study insights